Login / Signup

TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.

Michael GuentherSai Agash SurendranMichael HaasVolker HeinemannMichael von Bergwelt-BaildonJutta EngelJens WernerStefan BoeckSteffen Ormanns
Published in: British journal of cancer (2023)
The clinical trial registry identifier is NCT00440167.
Keyphrases
  • clinical trial
  • poor prognosis
  • study protocol
  • open label
  • binding protein
  • double blind
  • randomized controlled trial
  • long non coding rna
  • phase iii
  • radiation therapy
  • placebo controlled